These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2975758)

  • 1. Lysis of CR2-carrying cells by natural killer cells and by activated T-lymphocytes is enhanced by C3 fragments.
    Klein E; Ramos O; Sàrmay G; Yefenof E; Gergely J
    Mol Immunol; 1988 Nov; 25(11):1063-6. PubMed ID: 2975758
    [No Abstract]   [Full Text] [Related]  

  • 2. Ligands of CR2 do not interfere with C3 fragment fixation or enhanced NK sensitivity of Raji cells treated with human serum.
    Yefenof E; Ramos OF; Nilsson B; Klein E
    Immunol Lett; 1989 Jun; 21(4):303-6. PubMed ID: 2527817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
    Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
    J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes.
    Fischer E; Delibrias C; Kazatchkine MD
    J Immunol; 1991 Feb; 146(3):865-9. PubMed ID: 1703182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of activated C3 to lymphocyte-mediated cytolysis.
    Klein E; Sármay G; Ramos O; Yefenof E; Gergely J
    Mol Immunol; 1986 Nov; 23(11):1257-62. PubMed ID: 3821739
    [No Abstract]   [Full Text] [Related]  

  • 6. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
    Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
    Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
    Kuraya M; Yefenof E; Klein G; Klein E
    Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated NK sensitivity of Raji cells carrying acceptor-bound C3 fragments.
    Kai C; Sármay G; Ramos O; Yefenof E; Klein E
    Cell Immunol; 1988 May; 113(2):227-34. PubMed ID: 3359489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum.
    Ramos OF; Sármay G; Klein E; Yefenof E; Gergely J
    Proc Natl Acad Sci U S A; 1985 Aug; 82(16):5470-4. PubMed ID: 3895232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment.
    Cooper NR; Moore MD; Nemerow GR
    Annu Rev Immunol; 1988; 6():85-113. PubMed ID: 2838050
    [No Abstract]   [Full Text] [Related]  

  • 11. Proliferation of resting B cells is modulated by CR2 and CR1.
    Fingeroth JD; Heath ME; Ambrosino DM
    Immunol Lett; 1989 Jun; 21(4):291-301. PubMed ID: 2527816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
    Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
    J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CR2 ligands modulate human B cell activation.
    Bohnsack JF; Cooper NR
    J Immunol; 1988 Oct; 141(8):2569-76. PubMed ID: 2459218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of complement in the immune response.
    Feldbush TL; Hobbs MV; Severson CD; Ballas ZK; Weiler JM
    Fed Proc; 1984 Jul; 43(10):2548-52. PubMed ID: 6610570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors.
    Ramos OF; Kai C; Yefenof E; Klein E
    J Immunol; 1988 Feb; 140(4):1239-43. PubMed ID: 2963864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell cycle control of activated, synchronized murine B lymphocytes--roles of macrophages and complement C3.
    Melchers F; Erdei A; Corbel C; Leptin M; Schulz T; Dierich MP
    Mol Immunol; 1986 Nov; 23(11):1173-6. PubMed ID: 2950314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative pathway of complement activation by stimulated T lymphocytes. II. Elevation of cytotoxic potential against complement receptor-carrying cell lines.
    Ramos OF; Sármay G; Eggertsen G; Nilsson B; Klein E; Gergely J
    Eur J Immunol; 1987 Jul; 17(7):975-9. PubMed ID: 3111863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.
    Carel JC; Frazier B; Ley TJ; Holers VM
    J Immunol; 1989 Aug; 143(3):923-30. PubMed ID: 2473114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro studies on the immune regulatory role of complement receptors (C3) present on human B lymphocytes.
    Lobo PI; Burge JJ
    Eur J Immunol; 1982 Aug; 12(8):682-6. PubMed ID: 6982817
    [No Abstract]   [Full Text] [Related]  

  • 20. Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV-infected persons.
    June RA; Landay AL; Stefanik K; Lint TF; Spear GT
    Immunology; 1992 Jan; 75(1):59-65. PubMed ID: 1371493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.